Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B10 L-BPA BNCT in Recurrent Meningioma
NCT06668987Phase 2Completed
- Sponsor
- Heron Neutron Medical
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of borofalan (10B) in meningioma, sponsored by Heron Neutron Medical. Primary endpoint: Safety and efficacy of BNCT using B10 L-BPA at 6 months. Started Oct 2024; status: completed.
02
Drugs
borofalan (10B)
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06668987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668987.